| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000004a 4500 |
| 001 |
in00004504621 |
| 005 |
20191203131640.0 |
| 008 |
060509s2006 nyua b 001 0 eng |
| 010 |
|
|
|a 2006927190
|
| 016 |
7 |
|
|a 97918827X
|2 GyFmDB
|
| 020 |
|
|
|a 9780387340562
|
| 020 |
|
|
|a 0387340564
|
| 024 |
3 |
|
|a 9780387340562
|
| 029 |
1 |
|
|a OHX
|b har060049692
|
| 029 |
1 |
|
|a IG#
|b 0387340564
|
| 035 |
|
|
|a (OCoLC)ocm72436945
|
| 035 |
|
|
|z (UtOrBLW)41892
|
| 035 |
|
|
|a 59775
|
| 040 |
|
|
|a DLC
|c DLC
|d OHX
|d BAKER
|d IG#
|d TMV
|d UtOrBLW
|
| 049 |
|
|
|a TMVM
|c 1
|
| 050 |
0 |
0 |
|a RS420
|b .O68 2006
|
| 060 |
|
4 |
|a QV 744
|b O62 2006
|
| 072 |
|
7 |
|a RS
|2 lcco
|
| 245 |
0 |
0 |
|a Optimizing the "drug-like" properties of leads in drug discovery /
|c Ronald T. Borchardt [and others], editors.
|
| 264 |
|
1 |
|a New York, NY :
|b Springer,
|c [2006]
|
| 264 |
|
4 |
|c ©2006
|
| 300 |
|
|
|a x, 512 pages :
|b illustrations (some color) ;
|c 27 cm +
|e 1 CD-ROM.
|
| 336 |
|
|
|a text
|2 rdacontent
|b txt
|
| 337 |
|
|
|a unmediated
|2 rdamedia
|
| 338 |
|
|
|a volume
|2 rdacarrier
|b nc
|
| 490 |
1 |
|
|a Biotechnology: pharmaceutical aspects
|
| 500 |
|
|
|a "This book is based on proceedings from a worshop that took place in Parsippany, NJ on September 19-22, 2004." -- p. vii.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Strategic use of preclinical pharmacokinetic studies and In Vitro models in optimizing ADME properties of lead compounds -- Role of mechanistic transport studies in lead optimization -- Metabolic activation-role in toxicity and idiosyncratic reactions -- Case history - use of ADME studies for optimization of drug candidates -- Solubility, solubilization and dissolution in drug delivery during lead optimization -- Lipid-based systems, drug exposure and lead optimization -- Biopharmaceutics modeling and the role of dose and formulation on oral exposure -- Application of physicochemical data to support lead optimization by discovery teams -- Computational models supporting lead optimization in drug discovery -- Prodrug strategies for improving drug-like properties -- The application of multivariate data analysis to compound property optimization -- Case history : toxicology biomarker development using toxicogenomics -- Predicting idiosyncratic drug reactions -- Elementary predictive toxicology for advanced applications -- The application of PK/PD modeling and simulations during lead optimization -- Early preclinical evaluation of brain exposure in support of hit identification and lead optimization -- Optimizing biomarker development for clinical studies at the lead optimization stage of drug development -- The relevance of transporters in determining drug disposition
|
| 650 |
|
0 |
|a Drugs
|x Design.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Pharmaceutical chemistry.
|
| 650 |
|
2 |
|a Drug Design.
|
| 650 |
|
2 |
|a Chemistry, Pharmaceutical.
|
| 700 |
1 |
|
|a Borchardt, Ronald T.
|
| 830 |
|
0 |
|a Biotechnology (Arlington, Va.)
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s e625b7df-1612-3bc0-b17b-ea47f627c277
|i 330dd27b-eee2-3bdd-b5ed-23252ad75848
|t 0
|
| 952 |
f |
f |
|p ric
|a Texas A&M University
|b Rellis Campus
|c Joint Library Facility
|d Remote Storage
|t 0
|e QV 744 O62 2006
|h National Library of Medicine classification
|i unmediated -- volume
|m 323890193097B
|
| 998 |
f |
f |
|a QV 744 O62 2006
|t 0
|l Remote Storage
|